Influenza virus B infection drug market is anticipated to grow at a significant CAGR during the forecast period (2023-2029). Influenza viruses cause nose, throat, and sometimes lungs infection. Its symptoms include fever, a cough, sore throat, and body aches. Additionally, type B influenza can cause more severe symptoms than a common cold however, in some cases, there is no need for medical attention. The major factor accelerating the growth of the market is the increasing prevalence of influenza infection across the globe.
Furthermore, the market is also growing due to new FDA approvals. For instance, in November 2020, Roche announced the approval of a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) from the US Food and Drug Administration (FDA). It is the first single-dose influenza medicine approved for post-exposure prophylaxis used as a treatment to prevent influenza in people age 12 years and older due to coming in contact with someone with influenza.
Some major players in the market include AstraZeneca Plc, F. Hoffmann-La Roche AG, and GlaxoSmithKline Plc, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in July 2019, Gilead Sciences, Inc. announced that it has received an antiviral deal with Novartis. The deal was aimed to gain exclusive global rights to preclinical programmes which involve candidates for the treatment of various viral infections such as herpes viruses, human rhinovirus and influenza.
To Request a Sample of our Report on Influenza Virus B Infection Drug Market: https://www.omrglobal.com/request-sample/influenza-virus-b-infection-drug-market
Market Coverage
- The market number available for – 2022-2029
- Base year- 2022
- Forecast period- 2023-2029
Segment Covered-
- By Type
- By Distribution Channel
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– AstraZeneca Plc, F. Hoffmann-La Roche AG, and GlaxoSmithKline Plc, among others.
Influenza Virus B Infection Drug Market Report by Segment
By Type
- Peramivir
- Zanamivir
- Oseltamivir Phosphate
- Baloxavir Marboxil
- Others
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Others
A full Report of Influenza Virus B Infection Drug Market is Available @ https://www.omrglobal.com/industry-reports/influenza-virus-b-infection-drug-market
Influenza Virus B Infection Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
